| Literature DB >> 19659904 |
Karina Lidianne Alcântara Saraiva1, Amanda Karolina Soares E Silva, Maria Inês Wanderley, Araken Almeida De Araújo, José Roberto Botelho De Souza, Christina Alves Peixoto.
Abstract
The phosphodiesterase type 5 (PDE5) inhibitor, Sildenafil, is a novel, oral treatment approach for pulmonary hypertension. As Leydig cells present PDE5, this study was conducted to investigate the effects of the chronic treatment with Sildenafil (25 mg/kg) on male Swiss Webster mice steroidogenesis. After a 4-week long experimental design, Leydig cells were analysed by morphological and immunocytochemical procedures. Serum testosterone was assayed by radioimmunoassay. Leydig cells presented noteworthy ultrastructural alterations, such as a vesicular smooth endoplasmic reticulum, large vacuoles scattered through the cytoplasm, enlarged mitochondria with discontinue cristaes and whorle membranes with vesicles at the periphery, which are typical characteristics of an activated steroid-secreting cell. Important immunocytochemical labelling for steroidogenic acute regulatory protein, cytochrome P450 side-chain cleavage enzyme and testosterone were detected in isolated Leydig cells. In addition, Sildenafil-treated mice showed significant increased levels of total testosterone. The results obtained in the present study are consistent with the hypothesis that the accumulation of cyclic guanosine monophosphate by PDE5 inhibition could be involved in the androgen biosynthesis stimulation. Important clinical implications of hormonal disorders should be taken into account for patients with pulmonary hypertension.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19659904 PMCID: PMC2741156 DOI: 10.1111/j.1365-2613.2009.00660.x
Source DB: PubMed Journal: Int J Exp Pathol ISSN: 0959-9673 Impact factor: 1.925